Results 101 to 110 of about 62,633 (233)

Combined intranasal treatment for allergic rhinitis: an option for children under 12 years of age [PDF]

open access: yesExploration of Asthma & Allergy
Intranasal treatments combining corticosteroids with antihistamines are a safe and effective alternative for treating moderate to severe seasonal allergic rhinitis in children over 12 years of age and adults.
Alberto Vidal, Pedro Cortez
doaj   +1 more source

Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre‐Seasonal Short Courses of Allergen‐Specific Immunotherapy: A Long‐Term Open‐Label Extension Study

open access: yesClinical &Experimental Allergy, Volume 56, Issue 8, Page 893-903, August 2026.
3 years follow‐up study to a DBPC dose‐finding trial investigating subcutaneous immunotherapy with T502 in birch‐pollen induced allergic rhinoconjunctivitis. 154 birch‐pollen allergic adults received short‐course treatment of 10,000 mTU/mL of T502 for 2 years and were observed during the next season without treatment.
Ralph Mösges   +15 more
wiley   +1 more source

Comparative Efficacy of Intranasal Corticosteroids and Antihistamines in Enhancing Paediatric Quality of Life in Allergic Rhinoconjunctivitis

open access: yes
Clinical &Experimental Allergy, EarlyView.
Ellen Tameeris   +4 more
wiley   +1 more source

Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK‐air Study

open access: yesClinical &Experimental Allergy, Volume 56, Issue 8, Page 904-913, August 2026.
This mHealth study has shown that fixed combinations of intranasal antihistamines and corticosteroids were associated with higher quality of life than oral antihistamines and intranasal antihistamines. Both intranasal corticosteroids and oral antihistamines were associated with higher quality of life than intranasal antihistamines.
Nuno Lourenço‐Silva   +27 more
wiley   +1 more source

Stapokibart (CM310): A review in seasonal allergic rhinitis

open access: yesAmerican Journal of Otolaryngology
Stapokibart (CM310), a humanized anti-IL-4Rα monoclonal antibody, blocks IL-4/IL-13 signaling for type 2 inflammatory diseases like seasonal allergic rhinitis (SAR), where standard of care often fails.Assess stapokibart's efficacy on the primary endpoint (reflective Total Nasal Symptom Score, rTNSS) and safety as add-on therapy in SoC-inadequate ...
Ping, Xue, Jing, Yan, Jianwei, Li
openaire   +2 more sources

GWAS of Second‐Generation Antihistamine Use: Locus Specificity and Highlighted Signalling Pathways

open access: yes
Clinical &Experimental Allergy, EarlyView.
M. Niemi   +15 more
wiley   +1 more source

Longitudinal Analysis of Seasonal Variations in Intradermal Test Reactivity and Serum Allergen‐Specific Immunoglobulin E in Dogs With Atopic Dermatitis

open access: yesVeterinary Dermatology, Volume 37, Issue 4, Page 511-521, August 2026.
Background: In dogs with atopic dermatitis (AD), allergen testing is often timed to pollen exposure. However, data on seasonal effects on intradermal testing (IDT) and allergen‐specific immunoglobulin (Ig)E serology (SAT) are limited. Objectives: To evaluate the seasonal effects on IDT and SAT results in dogs with AD by comparing aeroallergen test ...
Jade Faucher   +3 more
wiley   +1 more source

T Cell O‐GlcNAcylation Increases in Patients With Allergic Rhinitis After the Natural Pollen Season

open access: yes
Clinical &Experimental Allergy, Volume 56, Issue 8, Page 926-928, August 2026.
Eduardo I. Cardenas   +7 more
wiley   +1 more source

The summer holiday association with allergic diseases among children and adolescents in Yunnan Province, China

open access: yesPreventive Medicine Reports
Objectives: The burden of allergic diseases in children and adolescents is on the rise in China. This study aimed to reveal the unique epidemiology characteristics and temporal aggregation patterns among them.
Xiangyu Yan   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy